Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis

Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although this novel drug has been widely used in clini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cui C, Lu H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	AMD VEGF Conbercept BCVA CRT Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/07601f6b648f404a9b87832cfbc69e5b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07601f6b648f404a9b87832cfbc69e5b
record_format	dspace
spelling	oai:doaj.org-article:07601f6b648f404a9b87832cfbc69e5b2021-12-02T00:34:00ZClinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis1178-1998https://doaj.org/article/07601f6b648f404a9b87832cfbc69e5b2017-12-01T00:00:00Zhttps://www.dovepress.com/clinical-observations-on-the-use-of-new-anti-vegf-drug-conbercept-in-a-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although this novel drug has been widely used in clinic, unlike other anti-VEGF drugs, validation and consensus on its method of clinical application and clinical safety have not yet been achieved.Methods: Relevant literature was searched on PubMed, Web of Science, China National Knowledge Internet, and Wanfang Data. Stata 12.0 was used for data analysis. Random- and fixed-effect models were employed to evaluate heterogeneity. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were utilized to measure the improvement of AMD patients.Results: In this study, we analyzed conbercept administration and compared its application with other control clinical methods for AMD treatment. Ranibizumab, triamcinolone, and traditional transpupillary thermotherapy (TTT) were administered in the control group. No differences were found in the BCVA and CRT improvement between the groups treated with conbercept and ranibizumab. However, the conbercept group had a lower serum VEGF level. After 3 months of treatment, conbercept led to a more significant BCVA and CRT improvement than triamcinolone. A more considerable BCVA improvement was observed in the group treated with conbercept than in the group treated with TTT. Moreover, even 6 months after the treatment, the effect of conbercept on CRT improvement was still more pronounced than that of TTT.Conclusion: In AMD patients, conbercept exerts considerably more positive effects on the long-term BCVA and CRT improvement than triamcinolone and TTT. The serum VEGF level in the conbercept group was lower than that in the ranibizumab group. Keywords: AMD, VEGF, conbercept, BCVA, CRTCui CLu HDove Medical PressarticleAMDVEGFConberceptBCVACRTGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 13, Pp 51-62 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	AMD VEGF Conbercept BCVA CRT Geriatrics RC952-954.6
spellingShingle	AMD VEGF Conbercept BCVA CRT Geriatrics RC952-954.6 Cui C Lu H Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
description	Chunmei Cui, Hong Lu Department of Ophthalmology, Beijing Chao-Yang Hospital, Beijing, China Purpose: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug approved for the treatment of age-related macular degeneration (AMD). Although this novel drug has been widely used in clinic, unlike other anti-VEGF drugs, validation and consensus on its method of clinical application and clinical safety have not yet been achieved.Methods: Relevant literature was searched on PubMed, Web of Science, China National Knowledge Internet, and Wanfang Data. Stata 12.0 was used for data analysis. Random- and fixed-effect models were employed to evaluate heterogeneity. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were utilized to measure the improvement of AMD patients.Results: In this study, we analyzed conbercept administration and compared its application with other control clinical methods for AMD treatment. Ranibizumab, triamcinolone, and traditional transpupillary thermotherapy (TTT) were administered in the control group. No differences were found in the BCVA and CRT improvement between the groups treated with conbercept and ranibizumab. However, the conbercept group had a lower serum VEGF level. After 3 months of treatment, conbercept led to a more significant BCVA and CRT improvement than triamcinolone. A more considerable BCVA improvement was observed in the group treated with conbercept than in the group treated with TTT. Moreover, even 6 months after the treatment, the effect of conbercept on CRT improvement was still more pronounced than that of TTT.Conclusion: In AMD patients, conbercept exerts considerably more positive effects on the long-term BCVA and CRT improvement than triamcinolone and TTT. The serum VEGF level in the conbercept group was lower than that in the ranibizumab group. Keywords: AMD, VEGF, conbercept, BCVA, CRT
format	article
author	Cui C Lu H
author_facet	Cui C Lu H
author_sort	Cui C
title	Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
title_short	Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
title_full	Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
title_fullStr	Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
title_full_unstemmed	Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
title_sort	clinical observations on the use of new anti-vegf drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/07601f6b648f404a9b87832cfbc69e5b
work_keys_str_mv	AT cuic clinicalobservationsontheuseofnewantivegfdrugconberceptinagerelatedmaculardegenerationtherapyametaanalysis AT luh clinicalobservationsontheuseofnewantivegfdrugconberceptinagerelatedmaculardegenerationtherapyametaanalysis
_version_	1718403595873812480

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis

Ejemplares similares